Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17105339 | 0.88 | PTGDR2 (0.40) | PTGDR2MAPTALDH1A1LMNAKMT2A | |
| SCHEMBL1749156 | 0.84 | PTGDR2 (0.46) | HSD11B1PTGDR2MAPTL3MBTL1ALDH1A1 | |
| SCHEMBL28694297 | 0.81 | PTGDR2 (0.46) | PTGDR2L3MBTL1ALDH1A1TDP1MEN1 | |
| SCHEMBL30668854 | 0.81 | PTGDR2 (0.44) | PTGDR2MAPTL3MBTL1ALDH1A1LMNA | |
| SCHEMBL1749021 | 0.81 | PTGDR2 (0.44) | HSD11B1PTGDR2L3MBTL1ALDH1A1MEN1 | |
| SCHEMBL13014031 | 0.81 | PTGDR2 (0.44) | PTGDR2MAPTL3MBTL1ALDH1A1LMNA | |
| SCHEMBL1354451 | 0.81 | PTGDR2 (0.44) | PTGDR2MAPTL3MBTL1ALDH1A1LMNA | |
| SCHEMBL1777233 | 0.80 | PTGDR2 (0.42) | PTGDR2MAPTL3MBTL1ALDH1A1MEN1 | |
| SCHEMBL1778080 | 0.79 | PTGDR2 (0.49) | PTGDR2L3MBTL1LMNAALDH3A1POLB | |
| SCHEMBL2994721 | 0.78 | PTGDR2 (0.39) | HSD11B1PTGDR2MAPTL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1990343-B1 | Azaindoles | AVENTIS PHARMA LTD (GB) | 2012-04-04 | — | — | EP | disclosed |
| US-7943616-B2 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2011-05-17 | — | — | US | disclosed |
| EP-2233486-A1 | Azaindoles | Aventis Pharma Limited (GB) | 2010-09-29 | — | — | EP | disclosed |
| EP-1263759-B1 | AZAINDOLES | AVENTIS PHARMA LTD (GB) | 2010-09-08 | — | — | EP | disclosed |
| EP-1990343-A2 | Azaindoles | Aventis Pharma Limited (GB) | 2008-11-12 | — | — | EP | disclosed |
| US-7227020-B2 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2007-06-05 | — | — | US | disclosed |
| US-20050267304-A1 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-01 | — | — | US | disclosed |
| US-6897207-B2 | Azaindoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| CN-1615873-A | Azaindoles compound | AVENTIS PHARMA LTD (GB) | 2005-05-18 | — | — | CN | disclosed |
| US-20040198737-A1 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2004-10-07 | — | — | US | disclosed |
| US-6770643-B2 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2004-08-03 | — | — | US | disclosed |
| US-20040053931-A1 | Azaindoles | AVENTIS PHARMACEUTICALS INC. | 2004-03-18 | — | — | US | disclosed |
| EP-1397360-A1 | AZAINDOLES | Aventis Pharma Limited (GB) | 2004-03-17 | — | — | EP | disclosed |
| US-20040009983-A1 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2004-01-15 | — | — | US | disclosed |
| WO-2003000688-A1 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2003-01-03 | — | — | WO | disclosed |
| EP-1263759-A2 | AZAINDOLES | Aventis Pharma Limited (GB) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001047922-A2 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198737-A1 | Azaindoles | CCNY, CCNO, CNKSR1 | HSD11B1 1830/4885PTGDR2 1659/4885MAPT 4861/4885 |
| US-20040053931-A1 | Azaindoles | CDKN1A, CDK7, CDK2 | HSD11B1 973/4885PTGDR2 803/4885MAPT 3999/4885 |
| US-20040009983-A1 | Azaindoles | CCNY, CCNO, CKS2 | HSD11B1 2360/4885PTGDR2 1357/4885MAPT 4875/4885 |
| US-20050267304-A1 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | MAP3K20, MAP3K12, MAP3K19 | HSD11B1 1439/4885PTGDR2 1583/4885MAPT 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.